Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Atlas Arteria ( (AU:ALX) ) has shared an announcement.
Atlas Arteria announced that the Supreme Court of Virginia upheld the State Corporation Commission’s decision to deny Toll Road Investors Partnership II’s toll rate application for the Dulles Greenway. This decision allows TRIP II’s federal case, which alleges constitutional violations, to proceed. TRIP II plans to submit a new rate application this year, indicating ongoing efforts to address toll rate issues.
The most recent analyst rating on (AU:ALX) stock is a Buy with a A$6.16 price target. To see the full list of analyst forecasts on Atlas Arteria stock, see the AU:ALX Stock Forecast page.
More about Atlas Arteria
Atlas Arteria is a company that partners to deliver world-class road experiences, focusing on creating long-term value through disciplined management and sustainable business practices. The group consists of toll road businesses in France, Germany, and the United States, including interests in the APRR, AREA, A79, and ADELAC motorway networks in France, the Chicago Skyway in the US, and the Warnow Tunnel in Germany.
Average Trading Volume: 2,146,891
Technical Sentiment Signal: Buy
Current Market Cap: A$7.3B
See more data about ALX stock on TipRanks’ Stock Analysis page.